R
Richard J. Colonno
Researcher at Bristol-Myers Squibb
Publications - 146
Citations - 14924
Richard J. Colonno is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Entecavir & Hepatitis B virus. The author has an hindex of 57, co-authored 141 publications receiving 14236 citations. Previous affiliations of Richard J. Colonno include Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
Ting-Tsung Chang,Robert G. Gish,Robert A. de Man,Adrián Gadano,Jose D. Sollano,You Chen Chao,Anna S. Lok,Kwang Hyub Han,Zachary Goodman,J. Zhu,Anne Cross,Deborah DeHertogh,R B Wilber,Richard J. Colonno,David Apelian +14 more
TL;DR: Among patients with HBeAg-positive chronic hepatitis B, the rates of histologic, virologic, and biochemical improvement are significantly higher with entecavir than with lamivudine, and the safety profile of the two agents is similar.
Journal ArticleDOI
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Ching-Lung Lai,Daniel Shouval,Anna S. Lok,Ting-Tsung Chang,Hugo Cheinquer,Zachary Goodman,Deborah DeHertogh,R B Wilber,Richard C. Zink,Anne Cross,Richard J. Colonno,Lori Fernandes +11 more
TL;DR: Among patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue, the rates of histologic improvement, virologic response, and normalization of alanine aminotransferase levels were significantly higher at 48 weeks with entecavir than with lamivudine.
Journal ArticleDOI
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao,Richard E. Nettles,Makonen Belema,Lawrence B. Snyder,Van N. Nguyen,Robert A. Fridell,Michael H. Serrano-Wu,David R. Langley,Jin-Hua Sun,Donald R. O'Boyle,Julie A. Lemm,Chunfu Wang,Jay O. Knipe,Caly Chien,Richard J. Colonno,Dennis M. Grasela,Nicholas A. Meanwell,Lawrence G. Hamann +17 more
TL;DR: These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations ofHCV inhibitors.
Journal ArticleDOI
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.
Daniel J. Tenney,Ronald E. Rose,Carl J. Baldick,Kevin A. Pokornowski,Betsy J. Eggers,Jie Fang,Michael Wichroski,Dong Xu,Joanna Yang,R B Wilber,Richard J. Colonno +10 more
TL;DR: Long‐term monitoring showed low rates of resistance in nucleoside‐naïve patients during 5 years of ETV therapy, corresponding with potent viral suppression and a high genetic barrier to resistance, support ETV as a primary therapy that enables prolonged treatment with potentiral suppression and minimal resistance.
Journal ArticleDOI
Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine
Daniel J. Tenney,Steven Levine,Ronald E. Rose,Ann W. Walsh,S P Weinheimer,Linda Discotto,Mary Jane Plym,Kevin A. Pokornowski,Cheng-Fang Yu,Peter W Angus,A Ayres,Angeline Bartholomeusz,William Sievert,Geoff Thompson,Nadia Warner,Stephen Locarnini,Richard J. Colonno +16 more
TL;DR: Infrequent ETV resistance can emerge during prolonged therapy, with selection of additional RT substitutions within a 3TCr HBV background, leading to reduced ETV susceptibility and treatment failure.